Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | ACR | P10323 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11860150 | 0.90 | PRSS1 (0.55) | ATMPRSS1ACRKDM4EMAOB | |
| SCHEMBL15836532 | 0.87 | ATM (0.48) | ATMPRSS1ACRKDM4EMAOB | |
| SCHEMBL869141 | 0.86 | CYP3A4 (0.58) | ATMPRSS1ACRKDM4EMAOB | |
| SCHEMBL10389716 | 0.85 | CYP3A4 (0.47) | ATMMAPTLMNA | |
| SCHEMBL30116329 | 0.82 | PRSS1 (0.55) | ATMPRSS1ACRKDM4EMAOB | |
| SCHEMBL9254070 | 0.82 | ATM (0.48) | ATMPRSS1ACRKDM4EMAOB | |
| SCHEMBL11904756 | 0.82 | PRSS1 (0.55) | ATMPRSS1ACRKDM4EMAOB | |
| SCHEMBL9575170 | 0.82 | PRSS1 (0.49) | ATMPRSS1ACRKDM4EMAOB | |
| SCHEMBL11848431 | 0.81 | PPARG (0.54) | ATMPRSS1ACRKDM4ECES2 | |
| SCHEMBL18697300 | 0.81 | PRSS1 (0.54) | ATMPRSS1ACRKDM4EMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174065-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | ZADEC APS (DK) | 2019-01-08 | — | — | US | disclosed |
| US-20160083411-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2016-03-24 | — | — | US | disclosed |
| US-9221860-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | ZADEC APS (DK) | 2015-12-29 | — | — | US | disclosed |
| EP-2625184-B1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2014-10-01 | — | — | EP | disclosed |
| US-20130310331-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2013-11-21 | — | — | US | disclosed |
| EP-2625184-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | Zadec ApS (DK) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012045363-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174065-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | PC, SLC5A1, SLC5A2 | ATM 4147/4885PRSS1 1701/4885ACR 2423/4885 |
| US-20160083411-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | PC, SLC5A1, SLC5A2 | ATM 4147/4885PRSS1 1701/4885ACR 2423/4885 |
| US-20130310331-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | PC, SLC5A1, SLC5A2 | ATM 4147/4885PRSS1 1701/4885ACR 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.